Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Idaho Technology; Arrayjet; TrovaGene; Pathway Genomics; Gentris, Bluechip

NEW YORK (GenomeWeb News) – Idaho Technology has changed its name to BioFire Diagnostics. The Salt Lake City-based molecular diagnostics firm said that the new name "more accurately reflect[s] its business strategy and strong momentum in the marketplace." BioFire makes the FilmArray pathogen detection system.

Edinburgh, UK-based Arrayjet has opened a sales office in Cambridge, Mass., in an effort to meet "increased demand" for its inkjet microarrayers and array manufacturing services in North America, the company said this week. Kelda Rawlings, Arrayjet's director of North American sales, will move from Edinburgh to the Boston area to support the US sales office.

TrovaGene said that it has achieved an intellectual property milestone under its license agreement with Qiagen subsidiary Ipsogen. San Diego-based Trovagene said the payment, the amount of which was not disclosed, was triggered by the issuance of a US patent cover the diagnostic use of nucleophosmin protein mutations in patients with acute myeloid leukemia. Ipsogen is one of several diagnostic developers and lab testing providers that have licensed rights from TrovaGene to NPM1 patents.

Pathway Genomics has launched a clinical trial with the Veterans Affairs San Diego Healthcare System to evaluate the firm's Pathway Fit saliva-based nutrigenetic test. The study is focused on the genetic associations of weight loss and gain in veterans enrolled in a national weight management program designed by the VA National Center for Health Promotion and Disease Prevention.

Pharmacogenomics and biorepository firm Gentris has signed up for Bluechip's early adopter program, gaining access to Bluechip's temperature sensing and tracking solution for cryogenic sample management. Under a partnership, Gentris also will expand its service model to include temperature tracking services.

In Brief This Week is a Friday column containing news items that our readers may have missed during the week.

The Scan

And a Fourth?

A fourth dose of the Pfizer-BioNTech SARS-CoV-2 vaccine in an Israeli study increased antibody levels but did not prevent Omicron variant infections, according to the Financial Times.

For Better Science Software

A virtual institute funded by former Google CEO Eric Schmidt's philanthropy aims to lure software engineers to academia, Science reports.

Recommendation Explanations

The New York Times writes that the US Centers for Disease Control and Prevention is straining to both make and explain decisions based on limited information.

Genome Research Papers on De Novo Mutation Rates, Polyploid Genotyping, Oncogene Epigenomic Translocation

In Genome Research this week: de novo mutations rates in hemoglobin subunits, analysis of variant calling methods for polyploid plants, and more.